PDCD1 and melanoma: To date, Ipilimumab is the only FDA approved anti- CTLA-4 antibody for the treatment of malignant melanoma and is used in clinics as a monotherapy or in combination with the anti-PD-1 antibody Nivolumab (2, 30).